Editorial

Published on 05 Nov 2024

Editorial: Towards continued and affordable accessibility of innovative drugs: sustainable development and efficient use of medicines

in Drugs Outcomes Research and Policies

Atse H. Huisman
Denise van den Berg
Saco de Visser
Bettina Ryll
Sahar Barjesteh van Waalwijk van Doorn-Khosrovani

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1490853

422 views

Original Research

Published on 05 Nov 2024

Evaluating nivolumab plus gemcitabine–cisplatin’s cost-effectiveness for aUC in China

in Drugs Outcomes Research and Policies

Kehui Meng
Heng Xiang
Meiyu Wu
Ouyang Xie
Andong Li
Chongqing Tan
Xiaomin Wan

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1382342

383 views

Correction

Published on 31 Oct 2024

Corrigendum: Impact of a DSS-supported medication review on the safety of drug therapy and quality of life in patients with antithrombotic therapy

in Drugs Outcomes Research and Policies

Tanja Elnaz Hassanzadeh
Carina Hohmann
Carsten Culmsee

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1507320

157 views

Review

Published on 31 Oct 2024

Opioid-free strategies for patient-controlled intravenous postoperative analgesia: a review of recent studies

in Drugs Outcomes Research and Policies

Xin Luo
Pan-Guo Rao
Xing-Heng Lei
Wen-Wen Yang
Bao-Zhen Liao
Rui Guo

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1454112

322 views

Original Research

Published on 28 Oct 2024

Sequential versus concomitant treatment of androgen receptor signaling inhibitors and docetaxel for metastatic hormone-sensitive prostate cancer: an network meta-analysis

in Drugs Outcomes Research and Policies

Chun Xing Li
Cong Ying Li
Yu Qiao Wang
Hua Liu
Zhan Jiang Yang
Xian Zhang
Guan Chun Wang
Lei Wang

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1462360

485 views

Original Research

Published on 25 Oct 2024

Safety assessment of sapropterin dihydrochloride: real-world adverse event analysis based on the FDA adverse event reporting system (FAERS)

in Drugs Outcomes Research and Policies

Jiahong Zhong
Xihui Yu
Zhuomiao Lin

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1486597

505 views

Brief Research Report

Published on 25 Oct 2024

Clinical risk factors of bevacizumab-related hypertension in patients with metastatic colorectal cancer: a retrospective study

in Drugs Outcomes Research and Policies

Zhuoling Zheng
Yihong Zhao
Jingwen Xie
Min Gao
Yiting Wang
Xiaoyan Li

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1463026

396 views

Original Research

Published on 24 Oct 2024

Pharmacist-led hospital intervention reduces unintentional patient-generated medication discrepancies after hospital discharge

in Drugs Outcomes Research and Policies

Maja Jošt
Lea Knez
Mitja Kos
Mojca Kerec Kos

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1483932

351 views

Original Research

Published on 23 Oct 2024

Transforming respiratory diseases management: a CMO-based hospital pharmaceutical care model

in Drugs Outcomes Research and Policies

Borja Zarate-Tamames
Noe Garin
Marta Calvin-Lamas
Sonia Jornet
Jose J. Martinez-Simon
Sara Garcia-Gil
Eva M. Garcia-Rebolledo
Ramon Morillo-Verdugo

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1461473

598 views

Original Research

Published on 21 Oct 2024

Atezolizumab plus bevacizumab and chemotherapy versus bevacizumab plus chemotherapy for metastatic cervical cancer: a cost-effectiveness analysis

in Drugs Outcomes Research and Policies

Hongfu Cai
Ling Fang
Jingwen Lin
Zhiwei Zheng

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1476256

512 views

Correction

Published on 17 Oct 2024

Corrigendum: Effectiveness of perindopril/amlodipine fixed-dose combination in the treatment of hypertension: a systematic review

in Drugs Outcomes Research and Policies

Truong Van Dat
Vo Linh Tu
Le Nguyen Anh Thu
Nguyen Nhat Anh Quang
Van Binh
Nguyen Thi Quynh Nga
Duong Hoang Loc
Tran Thi Hong Nguyen
Dao Ngoc Hien Tam
Hong-Han Huynh

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1485834

388 views

Clinical Trial

Published on 17 Oct 2024

Comparative analysis of the therapeutic efficacy of remimazolam tosylate and propofol in older adults undergoing painless endoscopic retrograde cholangiopancreatography

in Drugs Outcomes Research and Policies

Yu-quan Tian
Di-kun Chen
He-ming Zhang
Yong-mei Sun

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1404536

409 views

Original Research

Published on 15 Oct 2024

Willingness to pay and price elasticity of demand for long-acting injectable cabotegravir among men who have sex with men in Guangxi, China

in Drugs Outcomes Research and Policies

Shiwen Chen
Yuhua Ruan
Lu Liu
Hengyan Pei
Yu Jiang
Tengda Huang
Yuxia Wei
Litai Qin
Xuebin Dai
Yu Liu

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1367830

467 views

Original Research

Published on 15 Oct 2024

Drug-drug-interactions in patients with atrial fibrillation admitted to the emergency department

in Drugs Outcomes Research and Policies

Thorsten Bischof
Fiona Nagele
Marius M. Kalkofen
Maximilian E. O. Blechschmidt
Hans Domanovits
Markus Zeitlinger
Christian Schoergenhofer
Filippo Cacioppo

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1432713

711 views

Correction

Published on 14 Oct 2024

Corrigendum: Dose reduction of biologics in patients with plaque psoriasis: a review

in Drugs Outcomes Research and Policies

C. A. M. van Riel
C. A. J. Michielsens
M. E. van Muijen
L. S. van der Schoot
J. M. P. A. van den Reek
E. M. G. J. de Jong

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1505626

502 views

Systematic Review

Published on 10 Oct 2024

Network meta-analysis of treatment interventions for Helicobacter pylori infection in adult populations in East and Southeast Asia

in Drugs Outcomes Research and Policies

Li Zhang
Bo-Ren Li
Si-Tong Guo
Yan Li

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1462057

541 views

Navigation group

Articles

Editorial: Towards continued and affordable accessibility of innovative drugs: sustainable development and efficient use of medicines

Evaluating nivolumab plus gemcitabine–cisplatin’s cost-effectiveness for aUC in China

Corrigendum: Impact of a DSS-supported medication review on the safety of drug therapy and quality of life in patients with antithrombotic therapy

Opioid-free strategies for patient-controlled intravenous postoperative analgesia: a review of recent studies

Sequential versus concomitant treatment of androgen receptor signaling inhibitors and docetaxel for metastatic hormone-sensitive prostate cancer: an network meta-analysis

Safety assessment of sapropterin dihydrochloride: real-world adverse event analysis based on the FDA adverse event reporting system (FAERS)

Clinical risk factors of bevacizumab-related hypertension in patients with metastatic colorectal cancer: a retrospective study

Pharmacist-led hospital intervention reduces unintentional patient-generated medication discrepancies after hospital discharge

Transforming respiratory diseases management: a CMO-based hospital pharmaceutical care model

Atezolizumab plus bevacizumab and chemotherapy versus bevacizumab plus chemotherapy for metastatic cervical cancer: a cost-effectiveness analysis

Corrigendum: Effectiveness of perindopril/amlodipine fixed-dose combination in the treatment of hypertension: a systematic review

Comparative analysis of the therapeutic efficacy of remimazolam tosylate and propofol in older adults undergoing painless endoscopic retrograde cholangiopancreatography

Willingness to pay and price elasticity of demand for long-acting injectable cabotegravir among men who have sex with men in Guangxi, China

Drug-drug-interactions in patients with atrial fibrillation admitted to the emergency department

Corrigendum: Dose reduction of biologics in patients with plaque psoriasis: a review

Network meta-analysis of treatment interventions for Helicobacter pylori infection in adult populations in East and Southeast Asia